Understanding chronic toxicities in localized cancer treatments

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to quantify the impact of treatment-related chronic toxicities in women with non-metastatic breast cancer and early lung cancer. It will develop a comprehensive database to track these toxicities, describe their incidence and outcomes, and assess their psychological, social, and economic impacts. The study will also generate predictors for chronic toxicities based on biological criteria, with a focus on improving patient quality of life. A total of 14,750 women will be recruited across 26 cancer centers in France and followed for at least five years.

Why it matters

Who can join: the full rules

CANTO - Breast

Inclusion Criteria:

* Women,
* Aged 18 years and over,
* With an invasive breast cancer diagnosed by cytology or histology,
* No clinical evidence of metastasis at the time of inclusion,
* Untreated including scored for breast cancer surgery in progress,
* Patient receiving a social security system,
* Patient mastering the French language,
* Free and informed consent for additional biological samples, different questionnaires and collecting information on resource usage.
* (Since february 2022) Patient :

  1. Age \< 45 years at diagnostic
  2. Or CT2-3, cN0-3, HER2+(RH+or RH-) or RH-HER2-
  3. Or Eligible to Pembrozilumab, Olaparib, TDM1, Abemaciclib or Ribociclib

Exclusion Criteria:

* Metastatic breast cancer,
* Local recurrence of breast cancer,
* History of cancer within 5 years prior to entry into the trial other than basal cell skin or carcinoma in situ of the cervix,
* Already received treatment for breast cancer ongoing,
* Blood transfusion performed for less than six months,
* Persons deprived of liberty or under supervision (including guardianship).

CANTO - Lung

Inclusion Criteria:

* Aged 18 years and over, Having lung cancer diagnosed by cytology or histology or suspected cancer of the lung,
* Tumor cTX to cT4, cN0-3,
* No clinical evidence of metastasis at the time of inclusion (patients with metastases on extension assessment within 6 months following diagnosis will be removed from the study),
* Eligible for curative treatment by surgery or radiotherapy \* (note patients treated with exclusive chemotherapy, exclusive radiotherapy or exclusive stereotactic radiotherapy will be out of study)
* Lack of treatment received for current lung cancer, including surgical treatment
* Patient benefiting from a social protection scheme,
* Patient mastering the French language,
* Free and informed consent for additional biological samples, the different questionnaires and the collection of information on resource consumption.

Exclusion Criteria:

* Metastatic lung cancer,
* Local relapse of lung cancer,
* History of cancer within 3 years prior to study entry other than basal cell cutaneous or epithelioma in situ of the cervix,
* Treatment already received for current lung cancer,
* Blood transfusion carried out less than 6 months ago,
* Persons deprived of liberty or under guardianship (including curatorship).

Where it's running

• Gustave roussy
  Villejuif, France Recruiting

Study contacts

• Study coordinator: Catherine Gaudin
• Email: c-gaudin@unicancer.fr
• Phone: (0)6 71 48 27 76

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Managing chemotherapy side effects with a smartphone symptom app plus telenursing

  This trial tests whether a smartphone symptom-reporting app combined with a standardized telenursing program helps adults starting first-cycle chemotherapy for gastric, lung, breast, or colon cancer manage treatment side effects.

  Recruiting at 4 sites Ulsan University Hospital · Busan and 4 other locations · NCT07405931

• Skipping hormone therapy for some low-risk early breast cancer patients

  This trial tests whether certain older, postmenopausal women with very small, low-risk ER-positive HER2-negative breast cancers can skip hormone therapy after surgery without raising the chance of cancer coming back.

  Recruiting at 10 sites Phase 2 Unicancer · Angers and 40 other locations · NCT07661927

• Immunotherapy Master Trial for Advanced Cancers

  This trial tests a master protocol called METAREM to see if personalized immunotherapy strategies can help people with advanced or metastatic solid tumors.

  Recruiting Phase 2 Unicancer · Villejuif · NCT07431073

• Immunotherapy without chemotherapy for first-line advanced NSCLC with high PD-L1

  This trial tests pembrolizumab or cemiplimab as first-line treatment for adults with advanced NSCLC and high PD-L1, to see if immunotherapy alone can be effective without chemotherapy.

  Recruiting Phase 2 Unicancer · Bordeaux and 3 other locations · NCT07360743

• Neo‑adjuvant immunotherapy program for localized cancers

  This program tests tailored neo‑adjuvant immunotherapy approaches guided by rapid blood and fresh tumor profiling for people with localized solid cancers who are candidates for preoperative therapy.

  Recruiting Phase 2 Unicancer · Villejuif · NCT07262489

• Finding better ways to detect resistance to antibody‑drug conjugates in solid tumors and identify useful biomarkers

  This trial tests whether tissue and blood biomarkers collected before and after treatment can reveal why antibody‑drug conjugates stop working in adults with advanced breast, gastric, urothelial, or non‑small cell lung cancer.

  Recruiting Phase 2 Unicancer · Villejuif · NCT07259226

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.